Engineered immune cells take on tough lymphoma
NCT ID NCT05757700
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The study aims to find the safest dose and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T cells (CAR T cells) targeting CD19
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat B-cell lymphoma.
- What could go wrong
- This is an early phase 1 trial with only 30 participants, so it's too soon to know if it will work. There may be side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a single shot build a cancer army inside the body?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope